EU AI Act Legal Deep-Dive Part 1: What Can Medtech Expect, and When?
Cooley lawyers Elizabeth Anne Wright, Edward Turtle, Patrick Van Eecke and Daniel Millard were quoted in part one of Medtech Insight’s two-part series on the European Commission’s proposed AI Act, outlining the top four issues of the act that medtech firms should be aware of – including the current legislative stage of the act and when it might apply, which medical and in vitro diagnostic (IVD) devices are included in the scope of the act and how product risk classifications may differ from regulation rules, overlap with other regulations and the impact of the act for notified bodies.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.